Kaiser-Permanente, Los Angeles Medical Center, Los Angeles, California, USA.
Department of Cardiac Surgery, Southern California Permanente Medical Group, Los Angeles, California, USA.
Transfusion. 2024 Aug;64(8):1392-1401. doi: 10.1111/trf.17940. Epub 2024 Jul 9.
Kaiser-Permanente Los Angeles Medical Center (LAMC) is a 560 licensed bed facility that provides regional cardiovascular services, including 1200 open heart surgeries annually. In 2021, LAMC explored alternative therapies to offset the impact of pandemic-driven cryo AHF shortages, and implemented Pathogen Reduced Cryoprecipitated Fibrinogen Complex (also known as INTERCEPT Fibrinogen Complex or IFC). IFC is approved to treat and control bleeding associated with fibrinogen deficiency. Unlike cryo AHF, IFC has 5-day post-thaw shelf life with potential operational and clinical benefits. The implementation steps and the operational advantages to the LAMC Blood Bank are described.
Eighteen months post-implementation, the institution reviewed their product implementation experience and compared IFC with cryo AHF with a retrospective review of transfusion service and cardiac post-op data.
IFC significantly decreased product wastage rates and order-to-issue time. It did not significantly impact post-op product utilization or hospital length of stay (LOS) in cardiac surgery patients when compared with cryo AHF.
Implementation of IFC provides improved product supply stability, shorter turnaround times, and reduced wastage.
凯撒永久洛杉矶医疗中心（LAMC）是一家拥有 560 个许可床位的设施，提供区域心血管服务，包括每年 1200 例开放心脏手术。2021 年，LAMC 探索了替代疗法来抵消大流行驱动的冷沉淀 AHF 短缺的影响，并实施了病原体减少的冷沉淀纤维蛋白原复合物（也称为 INTERCEPT 纤维蛋白原复合物或 IFC）。IFC 获准用于治疗和控制与纤维蛋白原缺乏相关的出血。与冷沉淀 AHF 不同，IFC 具有 5 天的解冻后保质期，具有潜在的操作和临床优势。描述了 LAMC 血库的实施步骤和操作优势。
实施后 18 个月，该机构回顾了他们的产品实施经验，并通过回顾输血服务和心脏术后数据，将 IFC 与冷沉淀 AHF 进行了比较。
与冷沉淀 AHF 相比，IFC 显著降低了产品浪费率和从订单到发放的时间。它对心脏手术后患者的术后产品利用率或住院时间（LOS）没有显著影响。
IFC 的实施提供了更稳定的产品供应、更短的周转时间和减少的浪费。
